Summary Mec1-Ddc2 (ATR-ATRIP) controls the DNA damage checkpoint and shows
differential cell-cycle regulation in yeast. To find regulators of Mec1-Ddc2, we exploited a
mec1 mutant that retains catalytic activity in G2 and recruitment to stalled replication forks,
but which is compromised for the intra-S phase checkpoint. Two screens, one for
spontaneous survivors and an E-MAP screen for synthetic growth effects, identified loss of
PP4 phosphatase, pph3Δ and psy2Δ, as the strongest suppressors of mec1-100 lethality on …

Purpose: Although adoptive cell therapy can be highly effective for the treatment of patients
with melanoma, the application of this approach to the treatment of other solid tumors has
been limited. The observation that the cancer germline (CG) antigen NY-ESO-1 is expressed
in 70-80% and in approximately 25% of patients with synovial cell sarcoma and melanoma,
respectively, prompted us to perform this first-in-man clinical trial employing the adoptive
transfer of autologous PBMC that were retrovirally transduced with an NY-ESO-1 reactive …